Amgen-AstraZeneca Experimental Medicine Eases Psoriasis
This article is for subscribers only.
Amgen Inc. and AstraZeneca Plc’s experimental drug brodalumab eased symptoms of psoriasis at both doses tested in a key study needed for U.S. approval.
The medicine for moderate to severe plaque psoriasis dispersed the thick red patchy scales on patients’ skin, leaving it markedly clearer than those getting a placebo, the companies said today in a statement. The study is the first from the final round of tests on the drug. Two studies comparing it with Johnson & Johnson’s Stelara are expected by year end, said Sean Harper, executive vice president of research and development for Amgen, the world’s biggest biotechnology company by revenue.